DK3138916T3 - Immunogen sammensætning - Google Patents

Immunogen sammensætning Download PDF

Info

Publication number
DK3138916T3
DK3138916T3 DK16193340.3T DK16193340T DK3138916T3 DK 3138916 T3 DK3138916 T3 DK 3138916T3 DK 16193340 T DK16193340 T DK 16193340T DK 3138916 T3 DK3138916 T3 DK 3138916T3
Authority
DK
Denmark
Prior art keywords
immunogene
composition
immunogene composition
Prior art date
Application number
DK16193340.3T
Other languages
English (en)
Inventor
Cindy Castado
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46168484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3138916(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Application granted granted Critical
Publication of DK3138916T3 publication Critical patent/DK3138916T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
DK16193340.3T 2011-05-27 2012-05-25 Immunogen sammensætning DK3138916T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161490716P 2011-05-27 2011-05-27
US201161490734P 2011-05-27 2011-05-27
US201161490707P 2011-05-27 2011-05-27
EP12726374.7A EP2714911B1 (en) 2011-05-27 2012-05-25 Immunogenic composition

Publications (1)

Publication Number Publication Date
DK3138916T3 true DK3138916T3 (da) 2019-08-26

Family

ID=46168484

Family Applications (4)

Application Number Title Priority Date Filing Date
DK16193340.3T DK3138916T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning
DK19179871.9T DK3564378T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning
DK12726374.7T DK2714911T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning.
DK12724950.6T DK2714910T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK19179871.9T DK3564378T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning
DK12726374.7T DK2714911T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning.
DK12724950.6T DK2714910T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning

Country Status (25)

Country Link
US (5) US9409974B2 (da)
EP (6) EP4296361A3 (da)
JP (3) JP2014516532A (da)
KR (1) KR102014502B1 (da)
CN (3) CN103717742B (da)
BR (2) BR112013030395B1 (da)
CA (2) CA2837395C (da)
CY (3) CY1118599T1 (da)
DK (4) DK3138916T3 (da)
EA (1) EA030898B1 (da)
ES (3) ES2615737T3 (da)
FI (1) FI3564378T3 (da)
HR (4) HRP20231749T1 (da)
HU (4) HUE044772T2 (da)
IL (1) IL229529B2 (da)
LT (4) LT2714910T (da)
ME (1) ME02600B (da)
MX (1) MX346200B (da)
PL (4) PL3138916T3 (da)
PT (4) PT3138916T (da)
RS (1) RS55605B1 (da)
SG (1) SG195037A1 (da)
SI (4) SI2714911T1 (da)
SM (1) SMT201700110B (da)
WO (3) WO2012163810A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2753352T5 (pl) 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
BR122019017005B1 (pt) 2011-04-22 2022-03-29 Wyeth Llc Composições que se relacionam a uma toxina de clostridium difficile mutante
SG11201402375VA (en) * 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP6290918B2 (ja) 2012-12-05 2018-03-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
EP3271375B1 (en) 2015-02-19 2021-02-24 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
MX2020013623A (es) * 2018-06-19 2021-03-25 Glaxosmithkline Biologicals Sa Composicion inmunogenica.
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CN1176658A (zh) * 1994-10-24 1998-03-18 蛇药制品有限公司 治疗和预防艰难梭菌疾病的疫苗和抗毒素
JPH11509200A (ja) * 1995-07-07 1999-08-17 オラバックス インク. 粘膜アジュバントとしてのクロストリジウム・ディフィシール(Clostridium Difficile)トキシン
JP2002542169A (ja) * 1999-04-09 2002-12-10 テクラブ, インコーポレイテッド Clostridiumdifficileに対する、組換え毒素A/毒素Bワクチン
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
WO2001073030A2 (en) 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
PL2753352T5 (pl) 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens

Also Published As

Publication number Publication date
SG195037A1 (en) 2013-12-30
EP3138916A1 (en) 2017-03-08
IL229529B2 (en) 2023-05-01
SI3138916T1 (sl) 2019-08-30
KR20140019848A (ko) 2014-02-17
CA2837395A1 (en) 2012-12-06
US20170362309A1 (en) 2017-12-21
DK3564378T3 (da) 2024-01-08
CN103717742A (zh) 2014-04-09
EA201391548A1 (ru) 2014-06-30
DK2714910T3 (da) 2018-02-05
CY1118599T1 (el) 2017-07-12
BR112013030395B1 (pt) 2022-11-01
JP2014516532A (ja) 2014-07-17
SMT201700110B (it) 2017-03-08
WO2012163817A3 (en) 2013-03-21
HUE044772T2 (hu) 2019-11-28
PT2714910T (pt) 2018-03-09
WO2012163810A1 (en) 2012-12-06
LT3138916T (lt) 2019-08-26
CY1119916T1 (el) 2018-06-27
PT3564378T (pt) 2024-01-26
HUE030823T2 (en) 2017-06-28
US9409974B2 (en) 2016-08-09
MX2013013924A (es) 2013-12-16
CN107098977A (zh) 2017-08-29
PL2714911T3 (pl) 2017-05-31
WO2012163817A2 (en) 2012-12-06
US20140093529A1 (en) 2014-04-03
US9644024B2 (en) 2017-05-09
HRP20231749T1 (hr) 2024-03-15
EP4296361A2 (en) 2023-12-27
US20160159867A1 (en) 2016-06-09
PL3564378T3 (pl) 2024-03-11
BR112013030395A2 (pt) 2016-12-13
SI2714910T1 (en) 2018-04-30
SI3564378T1 (sl) 2024-02-29
ES2660468T3 (es) 2018-03-22
ES2743442T3 (es) 2020-02-19
HUE064492T2 (hu) 2024-03-28
JP2014522238A (ja) 2014-09-04
EP2714911A2 (en) 2014-04-09
EP3138916B1 (en) 2019-06-19
ES2615737T3 (es) 2017-06-08
EP4296361A3 (en) 2024-02-28
HUE037126T2 (hu) 2018-08-28
KR102014502B1 (ko) 2019-08-26
US9290565B2 (en) 2016-03-22
WO2012163811A1 (en) 2012-12-06
EP3327126A1 (en) 2018-05-30
CA2837393A1 (en) 2012-12-06
PL2714910T3 (pl) 2018-06-29
JP5952390B2 (ja) 2016-07-13
LT3564378T (lt) 2024-01-25
CA2837395C (en) 2021-05-18
US10093722B2 (en) 2018-10-09
RS55605B1 (sr) 2017-06-30
CY1121936T1 (el) 2020-10-14
US10377816B2 (en) 2019-08-13
PL3138916T3 (pl) 2019-11-29
HRP20180339T1 (hr) 2018-03-23
US20140178424A1 (en) 2014-06-26
EA030898B1 (ru) 2018-10-31
FI3564378T3 (fi) 2024-01-18
PT2714911T (pt) 2017-02-06
JP2017012160A (ja) 2017-01-19
MX346200B (es) 2017-03-10
SI2714911T1 (sl) 2017-03-31
HRP20170094T1 (hr) 2017-03-24
CN103717742B (zh) 2018-05-22
LT2714910T (lt) 2018-03-12
EP2714911B1 (en) 2016-11-30
ME02600B (me) 2017-06-20
HRP20191291T1 (hr) 2019-10-18
BR112013030396A2 (pt) 2016-12-13
EP2714910A1 (en) 2014-04-09
EP3564378B1 (en) 2023-11-01
PT3138916T (pt) 2019-09-17
EP3564378A1 (en) 2019-11-06
EP2714910B1 (en) 2018-01-10
US20170247421A1 (en) 2017-08-31
IL229529A0 (en) 2014-01-30
DK2714911T3 (da) 2017-02-27
LT2714911T (lt) 2017-02-10
IL229529B1 (en) 2023-01-01
CN103732750A (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
BR112013022112A2 (pt) composição
BR112013022102A2 (pt) composição
DK2686017T3 (da) Oftalmisk sammensætning
BR112014004395A2 (pt) composição
BR112012031667A2 (pt) composição
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
BR112013017183A2 (pt) composições de bepostatina
SMT201700110B (it) Composizione immunogena
BR112014002399A2 (pt) conjunto
BR112012032683A2 (pt) composição
DK2769050T3 (da) Propsensor
CO6910197A2 (es) Compuestos novedosos
BR112014000879A2 (pt) deflegmador
BR112013033808A2 (pt) composição
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
DE102011100082A8 (de) Traygreifvorrichtung
BR112012032980A2 (pt) composição
DE112012002915A5 (de) Ausrückeinrichtung
DK3141251T3 (da) Koloskopi - forberedelse
BR112014009761A2 (pt) composição oftálmica
BR112013030897A2 (pt) composição.
BR112014007030A2 (pt) composição
DE112011104936A5 (de) Stanzstauchniet
BR112014011723A2 (pt) composição antiperspirante